$LEXX
Lexaria Bioscience Corp. Stock $lexx

$lexx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000164033423002227 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$151.3K	$0.00	$226.2K
YoY Change	49.08%	-100.0%	-11.43%
Cost Of Revenue	$4.822K	$0.00	$31.50K
YoY Change	-69.47%	-100.0%	-56.15%
Gross Profit	$146.5K	$0.00	$194.7K
YoY Change	70.93%	-100.0%	6.08%
Gross Profit Margin	96.81%		86.07%
Selling, General & Admin	$711.1K	$570.0K	$3.060M
YoY Change	-30.66%	-53.54%	-46.55%
% of Gross Profit	485.55%		1571.58%
Research & Development	$574.5K	$500.0K	$3.667M
YoY Change	-30.74%	40.37%	98.99%
% of Gross Profit	392.26%		1883.19%
Depreciation & Amortization	$28.78K	$80.00K	$150.0K
YoY Change	16.38%	223.49%	46.03%
% of Gross Profit	19.65%		77.04%
Operating Expenses	$1.286M	$1.250M	$6.729M
YoY Change	-30.7%	-21.04%	-11.08%
Operating Profit	-$1.139M	-$1.250M	-$6.534M
YoY Change	-35.62%	-17.39%	-11.51%
Interest Expense	-$45.90K		-$180.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$45.90K		-$178.5K
YoY Change	-37.88%		-76.65%
Pretax Income	-$1.185M	-$1.250M	-$6.713M
YoY Change	-33.02%	-17.39%	-9.09%
Income Tax
% Of Pretax Income
Net Earnings	-$1.179M	-$1.240M	-$6.665M
YoY Change	-32.84%	-15.5%	-8.31%
Net Earnings / Revenue	-779.57%		-2946.36%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.13	-$0.15	-$1.01
COMMON SHARES
Basic Shares Outstanding	10.28M shares	8.092M shares
Diluted Shares Outstanding	9.052M shares		6.614M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.027M	$1.366M	$1.480M
YoY Change	-57.8%	-76.97%	-75.98%
Cash & Equivalents	$1.954M	$1.352M
Short-Term Investments	$72.43K	$14.05K	$130.0K
Other Short-Term Assets	$132.3K	$550.0K	$550.0K
YoY Change	-49.18%	-4.64%	-4.64%
Inventory		$0.00	$0.00
Prepaid Expenses	$132.3K	$546.8K
Receivables	$534.7K	$175.2K	$50.00K
Other Receivables	$534.7K	$130.0K	$130.0K
Total Short-Term Assets	$2.694M	$2.200M	$2.200M
YoY Change	-49.74%	-68.47%	-68.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$233.6K	$254.1K	$420.0K
YoY Change	-24.93%	-19.45%	14.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$933.1K	$884.2K	$880.0K
YoY Change	9.25%	3.25%	2.75%
TOTAL ASSETS
Total Short-Term Assets	$2.694M	$2.200M	$2.200M
Total Long-Term Assets	$933.1K	$884.2K	$880.0K
Total Assets	$3.627M	$3.084M	$3.080M
YoY Change	-41.63%	-60.63%	-60.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$92.13K	$230.0K	$230.0K
YoY Change	-46.95%	302.45%	302.45%
Accrued Expenses	$32.40K	$40.00K	$40.00K
YoY Change	-69.96%	-70.78%	-70.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$124.5K	$267.7K	$270.0K
YoY Change	-55.77%	37.98%	39.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$129.5K	$140.0K	$140.0K
YoY Change		1791.89%	1791.89%
Total Long-Term Liabilities	$129.5K	$140.0K	$140.0K
YoY Change		1791.64%	1791.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$124.5K	$267.7K	$270.0K
Total Long-Term Liabilities	$129.5K	$140.0K	$140.0K
Total Liabilities	$254.0K	$403.9K	$40.00K
YoY Change	-9.76%	100.51%	-134.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$46.94M	-$45.76M
YoY Change	14.9%	17.05%
Common Stock	$10.31K	$8.091K
YoY Change	73.26%	35.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.742M	$3.044M	$3.040M
YoY Change
Total Liabilities & Shareholders Equity	$3.627M	$3.084M	$3.080M
YoY Change	-41.63%	-60.63%	-60.68%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$1.179M	-$1.240M	-$6.665M
YoY Change	-32.84%	-15.5%	-8.31%
Depreciation, Depletion And Amortization	$28.78K	$80.00K	$150.0K
YoY Change	16.38%	223.49%	46.03%
Cash From Operating Activities	-$1.182M	-$1.620M	-$5.881M
YoY Change	-4.25%	37.68%	20.53%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$70.00K	$33.75K
YoY Change	-100.0%	-239.89%	-118.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$40.03K	-$70.00K	-$169.6K
YoY Change	14.88%	39.89%	-6.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.819M	-120.0K	$1.590M
YoY Change	-16338.58%	971.43%	-3664.42%
NET CHANGE
Cash From Operating Activities	-$1.182M	-1.620M	-$5.881M
Cash From Investing Activities	-$40.03K	-70.00K	-$169.6K
Cash From Financing Activities	$1.819M	-120.0K	$1.590M
Net Change In Cash	$602.1K	-1.810M	-$4.461M
YoY Change	-147.03%	46.22%	-12.61%
FREE CASH FLOW
Cash From Operating Activities	-$1.182M	-$1.620M	-$5.881M
Capital Expenditures	$0.00	$70.00K	$33.75K
Free Cash Flow	-$1.182M	-$1.690M	-$5.915M
YoY Change	-5.82%	50.01%	25.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001348362
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8091650	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5950998	shares
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2022	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	0	usd
CY2022	lxrp	Weighted Average Exercise Price Ending Balances WeightedAverageExercisePriceEndingBalances	8.04
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	424836	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.45
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-08-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-52138
CY2023	dei	Entity Registrant Name EntityRegistrantName	Lexaria Bioscience Corp
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2000871
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	#100 – 740 McCurdy Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Kelowna
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V1X 2P7
CY2023	dei	City Area Code CityAreaCode	250
CY2023	dei	Local Phone Number LocalPhoneNumber	765-6424
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001
CY2023	dei	Trading Symbol TradingSymbol	LEXX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	16.2	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10276641	shares
CY2023	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1352102	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5813218	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	125642	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	347335	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	175245	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	201784	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	38418	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	546783	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	576761	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	2199772	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	6977516	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	167446	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	52444	usd
CY2023Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	462625	usd
CY2022Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	488462	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	254143	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	315505	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	884214	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	856411	usd
CY2023Q3	us-gaap	Assets Assets	3083986	usd
CY2022Q3	us-gaap	Assets Assets	7833927	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	239941	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	151449	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27794	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	42587	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	267735	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	194036	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	136173	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7401	usd
CY2023Q3	us-gaap	Liabilities Liabilities	403908	usd
CY2022Q3	us-gaap	Liabilities Liabilities	201437	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8091650	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8091	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	5951	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48799454	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47041481	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45763427	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39098528	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	3044118	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	7948904	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-364040	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-316414	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2680078	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7632490	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3083986	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7833927	usd
CY2023	us-gaap	Revenues Revenues	226208	usd
CY2022	us-gaap	Revenues Revenues	255397	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31500	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	71841	usd
CY2023	us-gaap	Gross Profit GrossProfit	194708	usd
CY2022	us-gaap	Gross Profit GrossProfit	183556	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3666721	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1842675	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3062009	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4959920	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6728730	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6802595	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6534022	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6619039	usd
CY2023	us-gaap	Noninterest Income NoninterestIncome	43190	usd
CY2022	us-gaap	Noninterest Income NoninterestIncome	0	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-221693	usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-764614	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-178503	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-764614	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-6712525	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7383653	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6664899	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7269324	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-47626	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-114329	usd
CY2023	lxrp	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-1.01
CY2022	lxrp	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-1.24
CY2023	lxrp	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	6614066	shares
CY2022	lxrp	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	5885245	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-6712525	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7383653	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	170382	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	752591	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	145397	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	102718	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	106761	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	lxrp	Noncash Lease Expense NoncashLeaseExpense	41564	usd
CY2022	lxrp	Noncash Lease Expense NoncashLeaseExpense	38597	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-221693	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-764614	usd
CY2023	lxrp	Shares Issued For Services SharesIssuedForServices	0	usd
CY2022	lxrp	Shares Issued For Services SharesIssuedForServices	1200000	usd
CY2023	lxrp	Lease Accretion LeaseAccretion	2227	usd
CY2022	lxrp	Lease Accretion LeaseAccretion	5195	usd
CY2023	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	usd
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7926	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26539	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-137491	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	43069	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1979	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	29978	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-257508	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	88492	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50726	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-5223	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44814	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5881237	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4879339	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	135862	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	131448	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33748	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49192	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-169610	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-180640	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1589731	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	44600	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1589731	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-44600	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4461116	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5104579	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5813218	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10917797	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1352102	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5813218	usd
CY2023	lxrp	Income Taxes Paid Received IncomeTaxesPaidReceived	8214	usd
CY2022	lxrp	Income Taxes Paid Received IncomeTaxesPaidReceived	-4782	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	278108	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	156566	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13063552	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1200000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	752591	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7269324	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-114329	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7632490	usd
CY2023	lxrp	Shares Sold For Cash Amount SharesSoldForCashAmount	1589731	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170382	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6664899	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-47626	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2680078	usd
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	114456	shares
CY2023	us-gaap	Stockholders Equity Other StockholdersEquityOther	2000000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1589731	usd
CY2023Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1290000	usd
CY2023Q3	lxrp	Consulting Fee ConsultingFee	331811	usd
CY2022Q3	lxrp	Consulting Fee ConsultingFee	0	usd
CY2023Q3	lxrp	Licence Fees Receivable LicenceFeesReceivable	24635	usd
CY2022Q3	lxrp	Licence Fees Receivable LicenceFeesReceivable	37248	usd
CY2023Q3	lxrp	Prepaid Expenses Capital PrepaidExpensesCapital	25000	usd
CY2022Q3	lxrp	Prepaid Expenses Capital PrepaidExpensesCapital	96035	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	546783	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	576761	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	29060	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	106761	usd
CY2021Q3	lxrp	Trading Securitie Cost TradingSecuritieCost	1037025	usd
CY2021	lxrp	Unrealized Gains UnrealizedGains	16243	usd
CY2021	lxrp	Unrealized Losses UnrealizedLosses	-219427	usd
CY2021Q3	lxrp	Marketable Securities Unrealized Gain Loss Fair Value MarketableSecuritiesUnrealizedGainLossFairValue	833841	usd
CY2022Q3	lxrp	Trading Securitie Cost TradingSecuritieCost	1315132	usd
CY2022	lxrp	Unrealized Gains UnrealizedGains	134439	usd
CY2022	lxrp	Unrealized Losses UnrealizedLosses	-1102236	usd
CY2022Q3	lxrp	Marketable Securities Unrealized Gain Loss Fair Value MarketableSecuritiesUnrealizedGainLossFairValue	347335	usd
CY2023Q3	lxrp	Trading Securitie Cost TradingSecuritieCost	1315132	usd
CY2023	lxrp	Unrealized Gains UnrealizedGains	136295	usd
CY2023	lxrp	Unrealized Losses UnrealizedLosses	-1325785	usd
CY2023Q3	lxrp	Marketable Securities Unrealized Gain Loss Fair Value MarketableSecuritiesUnrealizedGainLossFairValue	125642	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	175245	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	201784	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	38418	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	38418	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	38418	usd
CY2023Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	40342	usd
CY2022Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	359863	usd
CY2023Q3	lxrp	Legal Accounting Fees LegalAccountingFees	36795	usd
CY2022Q3	lxrp	Legal Accounting Fees LegalAccountingFees	25000	usd
CY2023Q3	lxrp	Prepaid Licence And Filing Fees Due PrepaidLicenceAndFilingFeesDue	15668	usd
CY2022Q3	lxrp	Prepaid Licence And Filing Fees Due PrepaidLicenceAndFilingFeesDue	15000	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	97167	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	80863	usd
CY2023Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	462625	usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	457445	usd
CY2023	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	5180	usd
CY2022	us-gaap	Exploration Expense ExplorationExpense	7609	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.90
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.60
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.21
CY2023	lxrp	Product Revenues ProductRevenues	44167	usd
CY2023	lxrp	Licensing Usage LicensingUsage	146800	usd
CY2022	lxrp	Licensing Usage LicensingUsage	54560	usd
CY2022	lxrp	Effect Of Changes In Foreign And Long Term Tax Rates EffectOfChangesInForeignAndLongTermTaxRates	23625	usd
CY2023Q3	srt	Net Capital NetCapital	8637353	usd
CY2022Q3	srt	Net Capital NetCapital	7747485	usd
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities	14051	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	0	usd
CY2023	lxrp	Change In Valuation Allowance ChangeInValuationAllowance	-9580837	usd
CY2022	lxrp	Change In Valuation Allowance ChangeInValuationAllowance	-7865660	usd
CY2023	lxrp	Common Stock Shares Sold CommonStockSharesSold	34652	shares
CY2023	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	114456	shares
CY2023	lxrp	Proceeds From Issuance Common Shares Warrant ProceedsFromIssuanceCommonSharesWarrant	125122	usd
CY2023Q3	lxrp	Warrants Sale Price Per Unit WarrantsSalePricePerUnit	0.95
CY2022	lxrp	Proceeds From Issuance Common Shares Warrant ProceedsFromIssuanceCommonSharesWarrant	1600397	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2447275	shares
CY2022	lxrp	Weighted Average Exercise Price Beginning Balance WeightedAverageExercisePriceBeginningBalance	8.00
CY2022	lxrp	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	-25292	shares
CY2022	lxrp	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	4.57
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2421983	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4520483	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.98
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4520483	shares
CY2023Q3	lxrp	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	4.71
CY2023	lxrp	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P3Y3M10D
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	224299	shares
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1200000	usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.21
CY2023	lxrp	Number Of Stock Options Granted NumberOfStockOptionsGranted	267969	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	206170	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M
CY2023	lxrp	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisable	435186	shares
CY2023	lxrp	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisable	3.32
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	lxrp	Share Based Compensation Expense For Options Repricing ShareBasedCompensationExpenseForOptionsRepricing	25194	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	167446	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	52444	usd
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	44814	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	44599	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	538328	usd
CY2023Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	85000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.15
CY2023Q4	lxrp	Net Investment I Purchase NetInvestmentIPurchase	889272	usd
CY2023Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	729058	shares
CY2023Q4	lxrp	Business Of Description BusinessOfDescription	Company also agreed to issue and sell to the investor warrants to purchase up to 1,618,330 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant was $0.97 (to note the pre-funded warrants were issued at a price of $0.9699 and have an exercise price of $0.0001). The warrants will become exercisable six months from issuance, expire five and a half years from the issuance date, and have an exercise price of $0.97 per share
CY2023Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1290000	usd
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	729058	shares
CY2023Q4	lxrp	Proceeds From Issuance Initial Public Offering1 ProceedsFromIssuanceInitialPublicOffering1	73	usd
CY2023Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	566661	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.95
CY2023	dei	Auditor Firm AuditorFirmId	206

Files In Submission

Name	View Source	Status
lxrp-20230831_cal.xml	Edgar Link	unprocessable
lxrp-20230831_lab.xml	Edgar Link	unprocessable
0001640334-23-002227-index-headers.html	Edgar Link	pending
0001640334-23-002227-index.html	Edgar Link	pending
0001640334-23-002227.txt	Edgar Link	pending
0001640334-23-002227-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrp-20230831.xsd	Edgar Link	pending
lxrp_10k.htm	Edgar Link	pending
lxrp_ex231.htm	Edgar Link	pending
lxrp_ex232.htm	Edgar Link	pending
lxrp_ex311.htm	Edgar Link	pending
lxrp_ex312.htm	Edgar Link	pending
lxrp_ex321.htm	Edgar Link	pending
lxrp_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lxrp-20230831_def.xml	Edgar Link	unprocessable
lxrp-20230831_pre.xml	Edgar Link	unprocessable
lxrp_10k_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LEXX
Lexaria Bioscience Corp. Stock $lexx

2023 Q4 Form 10-K Financial Statement

#000164033423002227 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX Lexaria Bioscience Corp. Stock $lexx

2023 Q4 Form 10-K Financial Statement

#000164033423002227 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX
Lexaria Bioscience Corp. Stock $lexx